Josephine A. Wright
YOU?
Author Swipe
View article: Long‐Term Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( <scp>HIPEC</scp> ) for Pseudomyxoma Peritonei: A 22‐Year Single Institution Experience
Long‐Term Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( <span>HIPEC</span> ) for Pseudomyxoma Peritonei: A 22‐Year Single Institution Experience Open
Background Pseudomyxoma peritonei (PMP) is a rare condition, often associated with a poor prognosis if left untreated. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), have emerged as the preferred treatment for…
View article: Precision Medicine for Peritoneal Carcinomatosis—Current Advances in Organoid Drug Testing and Clinical Applicability
Precision Medicine for Peritoneal Carcinomatosis—Current Advances in Organoid Drug Testing and Clinical Applicability Open
Peritoneal carcinomatosis from gastrointestinal tumours is considered a poor prognostic factor, with a median overall survival of six to nine months in the absence of intervention. The advent of patient-derived organoid cultures (PDOs) has…
View article: Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing
Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing Open
Gastric cancer (GC) presents a significant health challenge and ranks as the fifth most common cancer in the world. Unfortunately, most patients with GC exhaust standard care treatment options due to late diagnosis and tumour heterogeneity…
View article: Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917
Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917 Open
The last decade has seen a rapid increase in studies utilising a genetically modified probiotic, Escherichia coli Nissle 1917 (EcN), as a chassis for cancer treatment and detection. This approach relies on the ability of EcN to home to and…
View article: Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases
Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases Open
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Cytokine-induced killer (CIK) cells are an adoptive immunotherapy reported to have strong anti-tumour activity across a range of cancers. They are a het…
View article: Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases
Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases Open
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Cytokine-induced killer (CIK) cells are an adoptive immunotherapy reported to have strong anti-tumour activity across a range of cancers. They are a het…
View article: Engineered bacteria detect tumor DNA
Engineered bacteria detect tumor DNA Open
Synthetic biology has developed sophisticated cellular biosensors to detect and respond to human disease. However, biosensors have not yet been engineered to detect specific extracellular DNA sequences and mutations. Here, we engineered na…
View article: Colorectal cancer detection and treatment with engineered probiotics
Colorectal cancer detection and treatment with engineered probiotics Open
Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment strategies. Here, we demonstrate the phenomenon of selective, long-term colonization of colorectal adenomas after oral…
View article: Figure S5 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S5 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Extended peritonoid drug sensitivity data
View article: Figure S3 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S3 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Extended data peritonoid drug testing platform, patient specific responses
View article: Figure S5 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S5 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Extended peritonoid drug sensitivity data
View article: Data from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Data from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Purpose:Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorectal cancer survival rates. We aimed to determine whether organoid testing could help guide precision treatment …
View article: Figure S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Characterisation of CRPM tissue and peritonoids.
View article: Figure S4 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S4 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Peritonoid sensitivity to standard care chemotherapeutic regimens ex vivo.
View article: Table S2 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Table S2 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Patient characteristics & analyses.
View article: Figure S3 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S3 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Extended data peritonoid drug testing platform, patient specific responses
View article: Table S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Table S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Summary of drug panels and peritonoid genomic information
View article: Supplementary Methods from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Supplementary Methods from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Supplementary Methods
View article: Figure S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Characterisation of CRPM tissue and peritonoids.
View article: The Antianginal Drug Perhexiline Displays Cytotoxicity against Colorectal Cancer Cells In Vitro: A Potential for Drug Repurposing
The Antianginal Drug Perhexiline Displays Cytotoxicity against Colorectal Cancer Cells In Vitro: A Potential for Drug Repurposing Open
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Perhexiline, a prophylactic anti-anginal drug, has been reported to have anti-tumour effects both in vitro and in vivo. Perhexiline as used clinically i…
View article: Engineered bacteria detect tumor DNA
Engineered bacteria detect tumor DNA Open
Summary Advances in bacterial engineering have catalysed the development of living cell diagnostics and therapeutics 1–3 , including microbes that respond to gut inflammation 4 , intestinal bleeding 5 , pathogens 6 and hypoxic tumors 7 . B…
View article: The BMP antagonist gremlin 1 contributes to the development of cortical excitatory neurons, motor balance and fear responses
The BMP antagonist gremlin 1 contributes to the development of cortical excitatory neurons, motor balance and fear responses Open
Bone morphogenetic protein (BMP) signaling is required for early forebrain development and cortical formation. How the endogenous modulators of BMP signaling regulate the structural and functional maturation of the developing brain remains…
View article: The BMP antagonist<i>Gremlin1</i>contributes to the development of cortical excitatory neurons, motor balance and fear responses
The BMP antagonist<i>Gremlin1</i>contributes to the development of cortical excitatory neurons, motor balance and fear responses Open
Bone morphogenetic protein (BMP) signaling is required for early forebrain development and cortical formation. How the endogenous modulators of BMP signaling regulate the structural and functional maturation of the developing brain remains…
View article: Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Purpose: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorectal cancer survival rates. We aimed to determine whether organoid testing could help guide precision treatment…